|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 27, 2016 ) Publisher's, 'Compugen Ltd. - Pipeline Review, H1 2016', provides an overview of the Compugen Ltd. pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Compugen Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Compugen Ltd. and features dormant and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Other Key Points in Report:
- The report provides a snapshot of the global therapeutic landscape of Compugen Ltd.
- The report reviews pipeline therapeutics for Compugen Ltd. by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Compugen Ltd. therapeutics and enlists all their major and minor projects
- The report assesses Compugen Ltd. therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Compugen Ltd.
Ask for Sample Report @ http://www.reportsweb.com/inquiry&RW0001242082/sample
Table of Content: An Overview
Table of Contents 2
List of Tables 5
List of Figures 5
Compugen Ltd. Snapshot 6
Compugen Ltd. Overview 6
Key Information 6
Key Facts 6
Compugen Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Compugen Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Compugen Ltd. - Pipeline Products Glance 14
Compugen Ltd. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Compugen Ltd. - Drug Profiles 16
CGEN-15001 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CGEN-15021 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001242082/discount
CGEN-15031 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CGEN-15051 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CGEN-15091 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CGEN-25009 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CGEN-856S 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody to Inhibit CGEN-15049 for Cancer 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody to Inhibit CGEN-15052 for Oncology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody to Inhibit CGEN-15092 for Multiple Sclerosis 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001242082/buy/1500
About Us:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Email: sales@reportsweb.com
Call: +1-646-491-9876
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
